Positive clinical results in patients with suspicion of colorectal cancer

Report this content
Oslo, Norway, March 22, 2007


The first results of Photocures clinical study using fluorescence diagnosis of colorectal polyps and tumours, show promising results.


Patients with suspicion of colorectal cancer are routinely examined by visual inspection of the colon (colonoscopy). The entire colon is examined to find tumors and polyps, but more than 20% of the lesions are missed which may progress to colorectal cancer.


Photocure has initiated development of its medical technology using fluorescence diagnosis to improve standard colonoscopy in patients with suspicion of colorectal cancer. Fluorescence diagnosis is already approved in Europe for diagnosis of bladder cancer.


Photocure is performing a dose-finding phase I/II study at two hospitals in Germany using fluorescence diagnosis in 30 patients with suspicion of colorectal cancer. Patients receive local instillation of hexaminolevulinate (HAL) before proceeding with colonoscopy using both white and blue (fluorescence) light.


The first results are presented at an endoscopy congress in Munich today by Dr Brigitte Mayinger, the leading investigator of the study. The first results show that fluorescence diagnosis improves detection of polyps. No systemic or local side effects related to the use of HAL are reported.


Kjetil Hestdal MD. Ph.D., President and CEO of Photocure comments: "We are pleased to see that our technology seems to improve diagnosis of colorectal cancer similar to what we have shown in patients with bladder cancer." 


Colorectal cancer is one of the most common cancers, but only about 50% of the patients are alive 5 years after diagnosis. This is due to invasive and metastatic disease in more than 50% of the patients at the time of diagnosis. Colorectal cancer develops over 10-15 years and by early diagnosis and treatment, mortality from this disease may be reduced by more than 90%. Colorectal polyps are quite common in the elderly population and health authorities in EU and US recommend that all women and men above 50 years should be screened. There are more than 10 million colonoscopies performed in EU and US annually.


 
Photocure ASA is a Norwegian pharmaceutical listed on Oslo Stock Exchange. The company develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technologies, targeting key dermatology and oncology markets.
 
Photocure has two products with sales and marketing approvals: Metvix®, which is a product developed for the treatment of skin cancer (basal cell carcinoma) and pre-cancerous skin lesions (actinic keratosis), and Hexvix®, which is developed for the diagnosis of bladder cancer. Both products are based on the same photodynamic technology, combining the drug known as a photosensitiser with a light source that activates the photosensitiser. Photocure aims to develop a pipeline of follow-on products and technologies.
 
 
For further information, contact:
Photocure ASA                                                          
Attn. Kjetil Hestdal (President and CEO) or Christian Fekete (CFO)
Kjetil Hestdal (kh@photocure.no), Mobile: +47 913 19 535
Christian Fekete (cf@photocure.no), Mobile: +47 916 42 938

Subscribe